Sigachi Industries Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹92Cr
- −18.9% YoY
- +0.1% QoQ
- Net profit
- ₹5Cr
- −29.7% YoY
- +67.6% QoQ
- Margin
- 13.25%
- −3.2 pp YoY
- +5.5 pp QoQ
Guidance rank: #15 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
What the Q4 FY26 call signalled
4 of 4 strong
The short version
Sigachi expects revenue for FY27 in the range of INR 650-675 crores, supported by incremental capacities from Dahej and Jhagadia and an improved product mix. FY27 revenue guidance: INR 650-675 crores with EBITDA margin of 18-20%, improved from current margins (~7%) - Utilization and margins expected to normalize by FY27 to mid-FY28, with margins reaching
From Sigachi Industries Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Sigachi expects revenue for FY27 in the range of INR 650-675 crores, supported by incremental capacities from Dahej and Jhagadia and an improved product mix.
- Expansion includes 12,000 metric tons capacity increase at Dahej H2 with CapEx of INR 106 crores, plus new CCS capacity (~INR 90 crores CapEx) expected to commercialize by Q1 FY28.
- Full capacity including MCC and CCS is expected to boost revenues significantly beyond FY27; the company targets INR 1000 crores turnover by around FY29.
- Volume growth expected from capacity expansion (from current 18,000 metric tons plus an additional 12,000 metric tons).
- API segment revenue is projected to increase from 14% to about 18-20% of total revenue, adding to topline growth.
2 more points from Sigachi Industries Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Ongoing CapEx for expanding MCC capacity by 12,000 metric tons at Dahej H2 with a cost of around INR 106 crores.
- CapEx for CCS project totaling around INR 90 crores, expected to commercialize by Q1 FY28.
- Dahej has 20 acres of land and Kurnool has 25 acres available for future capacity expansions.
2 more points from Sigachi Industries Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company mentioned ongoing business talks and some clients already lined up supporting revenue growth.
- Expected revenue from the new 12,000 metric tons capacity expansion is around INR 200-220 crores.
- From the Contract Custom Synthesis (CCS) segment, approximately INR 100 crores of revenue is anticipated.
- Demand for CCS is good, with inquiries and customers requesting dispatches alongside MCC, indicating a healthy order pipeline.
- Current focus is on gradually increasing MCC utilization from 75-80% to 90-95% during the year.
2 more points from Sigachi Industries Ltd's call on order book
Create a free account to keep reading this call
Sigachi Industries Ltd — Quarterly revenue & net profit
Sigachi Industries Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 92 | 114 | -18.9% | 92 | +0.1% |
| Operating profit (EBITDA) | 12 | 19 | -34.8% | 7 | +70.2% |
| Operating margin | 13.25% | 16.47% | -3.2 pp | 7.79% | +5.5 pp |
| Profit before tax | 6 | 14 | -58.7% | 1 | +461.4% |
| Net profit (PAT) | 5 | 7 | -29.7% | 3 | +67.6% |
| EPS (₹) | 0.13 | 0.18 | -27.8% | 0.08 | +62.5% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹113 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sigachi Industries's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Sigachi Industries Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sigachi Industries Ltd Q4 FY26 results?
Sigachi expects revenue for FY27 in the range of INR 650-675 crores, supported by incremental capacities from Dahej and Jhagadia and an improved product mix. FY27 revenue guidance: INR 650-675 crores with EBITDA margin of 18-20%, improved from current margins (~7%) - Utilization and margins expected to normalize by FY27 to mid-FY28, with margins reaching
What is Sigachi Industries Ltd share price analysis?
Sigachi Industries Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sigachi Industries Ltd planning capital expenditure?
Ongoing CapEx for expanding MCC capacity by 12,000 metric tons at Dahej H2 with a cost of around INR 106 crores.
Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
